HK1023599A1 - Cells for preventing graft rejection in transplantation and their uses. - Google Patents

Cells for preventing graft rejection in transplantation and their uses.

Info

Publication number
HK1023599A1
HK1023599A1 HK00102732A HK00102732A HK1023599A1 HK 1023599 A1 HK1023599 A1 HK 1023599A1 HK 00102732 A HK00102732 A HK 00102732A HK 00102732 A HK00102732 A HK 00102732A HK 1023599 A1 HK1023599 A1 HK 1023599A1
Authority
HK
Hong Kong
Prior art keywords
graft rejection
cells
lag
host
transplantation
Prior art date
Application number
HK00102732A
Other languages
English (en)
Inventor
Mauro Biffoni
Ruben Papoian
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of HK1023599A1 publication Critical patent/HK1023599A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK00102732A 1996-11-29 2000-05-05 Cells for preventing graft rejection in transplantation and their uses. HK1023599A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1996/005280 WO1998023748A1 (en) 1996-11-29 1996-11-29 Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)

Publications (1)

Publication Number Publication Date
HK1023599A1 true HK1023599A1 (en) 2000-09-15

Family

ID=8166413

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00102732A HK1023599A1 (en) 1996-11-29 2000-05-05 Cells for preventing graft rejection in transplantation and their uses.

Country Status (20)

Country Link
US (1) US6500422B2 (xx)
EP (1) EP0941329B1 (xx)
JP (1) JP3920928B2 (xx)
KR (1) KR100481230B1 (xx)
AR (1) AR018489A1 (xx)
AT (1) ATE271607T1 (xx)
AU (1) AU733825B2 (xx)
BR (1) BR9612821A (xx)
CA (1) CA2272130C (xx)
DE (1) DE69632967T2 (xx)
DK (1) DK0941329T3 (xx)
EA (1) EA003772B1 (xx)
ES (1) ES2225901T3 (xx)
HK (1) HK1023599A1 (xx)
IL (1) IL130168A (xx)
NO (1) NO324378B1 (xx)
PT (1) PT941329E (xx)
UA (1) UA73270C2 (xx)
WO (1) WO1998023748A1 (xx)
ZA (1) ZA9710737B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73270C2 (en) * 1996-11-29 2005-07-15 Application of genetically structured cells expressing lymphocytes activation gene (lag-3) on the surface for protection of transplant against rejection and a method for induction of specific protection against rejection of material being tranplanted
SI1897548T2 (sl) * 2003-02-28 2024-09-30 The Johns Hopkins University Regulacija celic T
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
BR122023024195A2 (pt) 2013-09-20 2023-12-26 Bristol-Myers Squibb Company Usos de anticorpos anti-lag-3 e anticorpos anti-pd-1
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
JP6622392B2 (ja) 2015-10-02 2019-12-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１とｔｉｍ３に特異的な二重特異性抗体
KR20180086502A (ko) 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항원-결합 단편
JP7426825B2 (ja) 2017-04-03 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート
KR102408873B1 (ko) 2017-04-05 2022-06-15 에프. 호프만-라 로슈 아게 Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
HUE065242T2 (hu) 2017-05-30 2024-05-28 Bristol Myers Squibb Co LAG-3-pozitív tumorok kezelése
AU2018275209A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
CA2189657C (fr) 1994-05-06 2002-03-12 Florence Faure Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
UA73270C2 (en) * 1996-11-29 2005-07-15 Application of genetically structured cells expressing lymphocytes activation gene (lag-3) on the surface for protection of transplant against rejection and a method for induction of specific protection against rejection of material being tranplanted

Also Published As

Publication number Publication date
NO992569L (no) 1999-05-27
EA199900507A1 (ru) 2000-02-28
KR20000053291A (ko) 2000-08-25
PT941329E (pt) 2004-11-30
EP0941329B1 (en) 2004-07-21
CA2272130C (en) 2007-10-23
EP0941329A1 (en) 1999-09-15
US6500422B2 (en) 2002-12-31
ATE271607T1 (de) 2004-08-15
US20020081282A1 (en) 2002-06-27
BR9612821A (pt) 2000-04-11
DK0941329T3 (da) 2004-11-29
AU733825B2 (en) 2001-05-24
JP3920928B2 (ja) 2007-05-30
IL130168A (en) 2006-09-05
KR100481230B1 (ko) 2005-04-07
AR018489A1 (es) 2001-11-28
JP2001505770A (ja) 2001-05-08
WO1998023748A1 (en) 1998-06-04
NO324378B1 (no) 2007-10-01
IL130168A0 (en) 2000-06-01
AU1066797A (en) 1998-06-22
DE69632967T2 (de) 2005-08-11
NO992569D0 (no) 1999-05-27
ZA9710737B (en) 1998-07-30
CA2272130A1 (en) 1998-06-04
DE69632967D1 (de) 2004-08-26
EA003772B1 (ru) 2003-08-28
UA73270C2 (en) 2005-07-15
ES2225901T3 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
HK1023599A1 (en) Cells for preventing graft rejection in transplantation and their uses.
Kumagai et al. Clinical application of autologous cultured epithelia for the treatment of burn wounds and burn scars
Coulomb et al. Advantage of the presence of living dermal fibroblasts within in vitro reconstructed skin for grafting in humans
US5397353A (en) Implant tissue
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
MXPA02007137A (es) Fuente de tejido hepatico.
CA2387542A1 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
WO1989007425A3 (en) Clinical developments using amniotic cells
CA2185447A1 (en) Treated tissue for implantation and preparation methods
WO1983001385A1 (en) Cell-seeding into fibrous lattices by means of centrifugation
MD970009A (en) Methods for inducing T cells tolerance to donor tissues or organs
NZ334400A (en) Method, instruments and kit for autologous transplantation comprising hemostatic barrier and a covering patch
WO2004009767A3 (en) Cell therapy for regeneration
AU2293795A (en) Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth (in vivo), utilizing amphipathic peptides
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
ATE300310T1 (de) Verfahren zur steigerung von hematopoietischen zellen
WO2001094541A3 (en) Human mesenchymal progenitor cell
JP2002529508A5 (ja) 移植における免疫応答抑制のための線維芽細胞または線維芽細胞からの上澄みを含む組成物およびその使用法
WO2002024244A3 (en) Method of preparing and processing transplant tissue
EP0690125A3 (en) Process for induction culture of cytotoxict lymphocytes having killing activity against tumor cells
AU2522997A (en) Method for killing unwanted target cells
AU7479596A (en) Induction of immunological tolerance
Fabre Epidermal allografts
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
WO2003029432A3 (en) Human mesenchymal progenitor cell

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20091129